An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the antic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fernández, Ariel, Sanguino, Angela, Peng, Zhenghong, Ozturk, Eylem, Chen, Jianping, Crespo, Alejandro, Wulf, Sarah, Shavrin, Aleksander, Qin, Chaoping, Ma, Jianpeng, Trent, Jonathan, Lin, Yvonne, Han, Hee-Dong, Mangala, Lingegowda S., Bankson, James A., Gelovani, Juri, Samarel, Allen, Bornmann, William, Sood, Anil K., Lopez-Berestein, Gabriel
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2007
Matèries:
Technical Advance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2104494/
https://ncbi.nlm.nih.gov/pubmed/18060038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI32373
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars